Compare Stocks: AMLX, IONS, CYTK, and SYRE

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
AMLX Amylyx Pharmaceuticals	$38.66 -2.5%	$20.37	$8.46 ▼ $41.14	$4.31B	-0.21	3.81 million shs	4.64 million shs
CYTK Cytokinetics	$76.84 -0.4%	$80.09	$35.22 ▼ $88.31	$9.56B	0.38	1.92 million shs	1.52 million shs
IONS Ionis Pharmaceuticals	$59.74 +1.7%	$64.20	$41.71 ▼ $86.74	$9.93B	0.41	2.48 million shs	2.72 million shs
SYRE Spyre Therapeutics	$106.49 -1.2%	$97.22	$14.51 ▼ $110.18	$9.36B	3.03	844,575 shs	1.01 million shs

7 Stocks to Buy And Hold Forever

Click the link to see MarketBeat's list of seven stocks and why their long-term outlooks are very promising.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
AMLX Amylyx Pharmaceuticals	0.00%	+78.73%	+119.78%	+184.68%	+381.44%
CYTK Cytokinetics	0.00%	+3.66%	-6.20%	-0.13%	+105.89%
IONS Ionis Pharmaceuticals	0.00%	+4.37%	+6.93%	-20.94%	+39.55%
SYRE Spyre Therapeutics	0.00%	+2.76%	+6.50%	+43.81%	+551.31%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
AMLX Amylyx Pharmaceuticals	$38.66 -2.5%	$20.37	$8.46 ▼ $41.14	$4.31B	-0.21	3.81 million shs	4.64 million shs
CYTK Cytokinetics	$76.84 -0.4%	$80.09	$35.22 ▼ $88.31	$9.56B	0.38	1.92 million shs	1.52 million shs
IONS Ionis Pharmaceuticals	$59.74 +1.7%	$64.20	$41.71 ▼ $86.74	$9.93B	0.41	2.48 million shs	2.72 million shs
SYRE Spyre Therapeutics	$106.49 -1.2%	$97.22	$14.51 ▼ $110.18	$9.36B	3.03	844,575 shs	1.01 million shs

7 Stocks to Buy And Hold Forever

Click the link to see MarketBeat's list of seven stocks and why their long-term outlooks are very promising.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
AMLX Amylyx Pharmaceuticals	0.00%	+78.73%	+119.78%	+184.68%	+381.44%
CYTK Cytokinetics	0.00%	+3.66%	-6.20%	-0.13%	+105.89%
IONS Ionis Pharmaceuticals	0.00%	+4.37%	+6.93%	-20.94%	+39.55%
SYRE Spyre Therapeutics	0.00%	+2.76%	+6.50%	+43.81%	+551.31%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
AMLX Amylyx Pharmaceuticals	3.00	Buy	$36.25	-6.23% Downside
CYTK Cytokinetics	2.86	Moderate Buy	$102.20	33.00% Upside
IONS Ionis Pharmaceuticals	2.73	Moderate Buy	$94.15	57.60% Upside
SYRE Spyre Therapeutics	2.87	Moderate Buy	$111.69	4.89% Upside

Current Analyst Ratings Breakdown

Latest AMLX, IONS, CYTK, and SYRE Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/19/2026	AMLX Amylyx Pharmaceuticals	Guggenheim Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Buy	$40.00 ➝ $55.00
8/19/2026	AMLX Amylyx Pharmaceuticals	Robert W. Baird Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Outperform	$28.00 ➝ $52.00
8/19/2026	IONS Ionis Pharmaceuticals	BMO Capital Markets Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Outperform ➝ Market Perform	$60.00
8/18/2026	AMLX Amylyx Pharmaceuticals	Mizuho Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Outperform	$30.00 ➝ $42.00
8/18/2026	AMLX Amylyx Pharmaceuticals	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Buy	$34.00 ➝ $55.00
8/18/2026	IONS Ionis Pharmaceuticals	BMO Capital Markets Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Hold
8/17/2026	AMLX Amylyx Pharmaceuticals	Wolfe Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Strong-Buy
8/17/2026	AMLX Amylyx Pharmaceuticals	Mizuho Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Outperform	$24.00 ➝ $30.00
8/14/2026	CYTK Cytokinetics	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy
8/13/2026	CYTK Cytokinetics	Barclays Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Overweight	$95.00 ➝ $110.00
8/13/2026	CYTK Cytokinetics	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Overweight	$97.00 ➝ $103.00

(Data available from 8/23/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
AMLX Amylyx Pharmaceuticals	$87.37M	49.30	N/A	N/A	$2.15 per share	17.98
CYTK Cytokinetics	$88.04M	108.60	N/A	N/A	($1.39) per share	-55.28
IONS Ionis Pharmaceuticals	$944M	10.52	N/A	N/A	$2.65 per share	22.54
SYRE Spyre Therapeutics	$890K	10,522.17	N/A	N/A	$10.86 per share	9.81

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
AMLX Amylyx Pharmaceuticals	-$144.74M	-$1.43	N/A	N/A	N/A	N/A	-52.92%	-48.53%	11/5/2026 (Estimated)
CYTK Cytokinetics	-$784.96M	-$7.22	N/A	N/A	N/A	-1,321.12%	N/A	-51.01%	11/4/2026 (Estimated)
IONS Ionis Pharmaceuticals	-$381.39M	-$3.46	N/A	N/A	N/A	-64.76%	-111.08%	-17.41%	11/4/2026 (Estimated)
SYRE Spyre Therapeutics	-$155.20M	-$1.95	N/A	N/A	N/A	N/A	-30.74%	-22.23%	11/3/2026 (Estimated)

Latest AMLX, IONS, CYTK, and SYRE Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/6/2026	Q2 2026	AMLX Amylyx Pharmaceuticals	-$0.3609	-$0.39	-$0.0291	-$0.39	N/A	N/A
8/6/2026	Q2 2026	CYTK Cytokinetics	-$1.63	-$1.50	+$0.13	-$1.50	$17.59 million	$28.62 million
8/4/2026	Q2 2026	SYRE Spyre Therapeutics	-$0.7589	-$0.36	+$0.3989	-$0.36	N/A	N/A
7/29/2026	Q2 2026	IONS Ionis Pharmaceuticals	-$1.08	-$0.69	+$0.39	-$0.69	$189.10 million	$267.95 million

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
AMLX Amylyx Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
CYTK Cytokinetics	N/A	N/A	N/A	N/A	N/A
IONS Ionis Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
SYRE Spyre Therapeutics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
AMLX Amylyx Pharmaceuticals	N/A	12.12	12.12
CYTK Cytokinetics	N/A	6.66	6.66
IONS Ionis Pharmaceuticals	3.07	7.89	7.73
SYRE Spyre Therapeutics	N/A	18.53	18.53

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
AMLX Amylyx Pharmaceuticals	95.84%
CYTK Cytokinetics	N/A
IONS Ionis Pharmaceuticals	93.86%
SYRE Spyre Therapeutics	80.39%

Insider Ownership

Company	Insider Ownership
AMLX Amylyx Pharmaceuticals	10.90%
CYTK Cytokinetics	2.60%
IONS Ionis Pharmaceuticals	1.81%
SYRE Spyre Therapeutics	15.69%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
AMLX Amylyx Pharmaceuticals	200	111.42 million	99.28 million	Optionable
CYTK Cytokinetics	250	124.43 million	121.20 million	Optionable
IONS Ionis Pharmaceuticals	1,402	166.18 million	163.18 million	Optionable
SYRE Spyre Therapeutics	73	87.94 million	74.14 million	Optionable

AMLX, IONS, CYTK, and SYRE Headlines

Recent News About These Companies

Spyre Therapeutics, Inc. (NASDAQ:SYRE) Receives Consensus Recommendation of "Moderate Buy" from Brokerages

August 21 at 4:28 AM | marketbeat.com

This stock’s already up nearly 600% over the past year

August 19, 2026 | msn.com

Spyre Therapeutics (NASDAQ:SYRE) Hits New 52-Week High - Here's What Happened

August 18, 2026 | marketbeat.com

LifeSci Capital Reaffirms Their Buy Rating on Spyre Therapeutics (SYRE)

August 17, 2026 | theglobeandmail.com

Handelsbanken Fonder AB Makes New $2.31 Million Investment in Spyre Therapeutics, Inc. $SYRE

August 17, 2026 | marketbeat.com

Spyre Therapeutics (NASDAQ:SYRE) Downgraded to Sell Rating by Wall Street Zen

August 16, 2026 | americanbankingnews.com

Wall Street Zen Downgrades Spyre Therapeutics (NASDAQ:SYRE) to Sell

August 16, 2026 | marketbeat.com

Wedbush Keeps Their Buy Rating on Spyre Therapeutics (SYRE)

August 14, 2026 | theglobeandmail.com

Dimensional Fund Advisors LP Sells 29,593 Shares of Spyre Therapeutics, Inc. $SYRE

August 14, 2026 | marketbeat.com

BTIG Research Increases Spyre Therapeutics (NASDAQ:SYRE) Price Target to $132.00

August 13, 2026 | americanbankingnews.com

Spyre Therapeutics Launches Program, Mid-Stage Trial for Drug Combination to Treat Hidradenitis Suppurativa

August 11, 2026 | finance.yahoo.com

Spyre Therapeutics (NASDAQ:SYRE) Stock Price Expected to Rise, BTIG Research Analyst Says

August 11, 2026 | marketbeat.com

Spyre Therapeutics, Inc. $SYRE Shares Bought by Bank of America Corp DE

August 11, 2026 | marketbeat.com

Spyre Therapeutics (NASDAQ:SYRE) Director Sells 18,000 Shares

August 10, 2026 | marketbeat.com

Spyre Therapeutics Announces Launch of SPY772 Program and Initiation of Phase 2 SKYLIGHT Trial in Hidradenitis Suppurativa

August 10, 2026 | markets.businessinsider.com

California State Teachers Retirement System Purchases 11,204 Shares of Spyre Therapeutics, Inc. $SYRE

August 10, 2026 | marketbeat.com

Can Spyre Therapeutics (SYRE) Justify Its Premium After Positive Phase 2 Data?

August 9, 2026 | finance.yahoo.com

Spyre Therapeutics (NASDAQ:SYRE) Stock Rating Upgraded by Wall Street Zen

August 8, 2026 | marketbeat.com

Spyre Therapeutics Announces Grants of Inducement Awards

August 7, 2026 | globenewswire.com

Analysts Have Conflicting Sentiments on These Healthcare Companies: Spyre Therapeutics (SYRE), Ultragenyx Pharmaceutical (RARE) and Bruker (BRKR)

August 7, 2026 | theglobeandmail.com

Scott Burrows Sells 7,500 Shares of Spyre Therapeutics (NASDAQ:SYRE) Stock

August 6, 2026 | insidertrades.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

AMLX, IONS, CYTK, and SYRE Company Descriptions

Amylyx Pharmaceuticals NASDAQ:AMLX

$38.66 -1.00 (-2.52%)

As of 08/21/2026 04:00 PM Eastern

Amylyx Pharmaceuticals, Inc is a biopharmaceutical company dedicated to developing treatments for rare and debilitating neurological diseases. Founded in 2013 and headquartered in Cambridge, Massachusetts, the company focuses on leveraging novel approaches to target cellular pathways implicated in neurodegeneration. Amylyx's research platform centers on small-molecule therapies designed to protect neurons and support cellular health in patients with conditions that currently have limited or no disease-modifying treatment options.

Cytokinetics NASDAQ:CYTK

$76.84 -0.34 (-0.44%)

As of 08/21/2026 04:00 PM Eastern

Cytokinetics, Incorporated, a late-stage biopharmaceutical company, focuses on discovering, developing, and commercializing muscle activators and inhibitors as potential treatments for debilitating diseases. The company develops small molecule drug candidates primarily engineered to impact muscle function and contractility. Its drug candidates include omecamtiv mecarbil, a novel cardiac myosin activator that is in Phase III clinical trial in patients with heart failure. The company also develops CK-136, a novel cardiac troponin activator that is in Phase I clinical trial; CK-586, a small molecule cardiac myosin inhibitor, that is in Phase I clinical trial; and aficamten, a novel cardiac myosin inhibitor, which is in Phase III clinical trial for the treatment of patients with symptomatic obstructive hypertrophic cardiomyopathy. Cytokinetics, Incorporated has a strategic alliance with Ji Xing Pharmaceuticals Limited. The company was incorporated in 1997 and is headquartered in South San Francisco, California.

Ionis Pharmaceuticals NASDAQ:IONS

$59.74 +0.98 (+1.67%)

As of 08/21/2026 04:00 PM Eastern

Ionis Pharmaceuticals, Inc. discovers and develops RNA-targeted therapeutics in the United States. The company offers SPINRAZA for spinal muscular atrophy (SMA) in pediatric and adult patients; TEGSEDI, an antisense injection for the treatment of polyneuropathy caused by hereditary transthyretin amyloidosis in adults; and WAYLIVRA, an antisense medicine for treatment for familial chylomicronemia syndrome (FCS) and familial partial lipodystrophy. It also develops medicines for various indications that are in phase 3 study, including Eplontersen as a monthly self-administered subcutaneous injection to treat all types of ATTR; Olezarsen for patients with FCS and severe hypertriglyceridemia (SHTG); Donidalorsen for patients with hereditary angioedema; ION363 for patients with amyotrophic lateral sclerosis; Tofersen to inhibit the production of superoxide dismutase 1; Pelacarsen for patients with established cardiovascular disease and elevated lipoprotein(a); and Bepirovirsen to inhibit the production of viral proteins associated with hepatitis B virus. In addition, the company develops IONIS-FB-LRx to inhibit the production of complement factor B and the alternative complement pathway; and ION224 to reduce the production of diacylglycerol acyltransferase 2. It has a strategic collaboration with Biogen for the treatment of neurological disorders; and collaboration and license agreement with Metagenomi, Inc, AstraZeneca, Bayer AG, GlaxoSmithKline plc, Novartis, Roche, Swedish Orphan Biovitrum AB, and PTC Therapeutics. The company was incorporated in 1989 and is based in Carlsbad, California.

Spyre Therapeutics NASDAQ:SYRE

$106.49 -1.30 (-1.21%)

As of 08/21/2026 04:00 PM Eastern

Spyre Therapeutics, Inc., a preclinical stage biotechnology company, focuses on developing therapeutics for patients living with inflammatory bowel disease (IBD). It develops SPY001, a human monoclonal immunoglobulin G1 antibody designed to bind selectively to the a4ß7 integrin being developed for the treatment of IBD (ulcerative colitis and Crohn's disease). The company is also developing SPY002, a human monoclonal antibody (mAb)candidates designed to bind to tumor necrosis factor-like ligand 1A; and SPY120, a combination of SPY001 (anti-a4ß7) and SPY002 (anti-TL1A) antibodies, which are in preclinical studies. In addition, its other early-stage programs include SPY003, an anti-IL-23 mAb; SPY004, a novel mechanism of action (MOA) mAb; SPY130, a combination of anti-a4ß7 and anti-IL-23 mAbs; and SPY230, a combination of anti-TL1A and anti-IL-23 mAbs. The company was formerly known as Aeglea BioTherapeutics, Inc. and changed its name to Spyre Therapeutics, Inc. in November 2023. Spyre Therapeutics, Inc. was incorporated in 2013 and is based in Waltham, Massachusetts.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest AMLX, IONS, CYTK, and SYRE Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest AMLX, IONS, CYTK, and SYRE Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

AMLX, IONS, CYTK, and SYRE Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

AMLX, IONS, CYTK, and SYRE Company Descriptions

Amylyx Pharmaceuticals NASDAQ:AMLX

Cytokinetics NASDAQ:CYTK

Ionis Pharmaceuticals NASDAQ:IONS

Spyre Therapeutics NASDAQ:SYRE

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest AMLX, IONS, CYTK, and SYRE Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest AMLX, IONS, CYTK, and SYRE Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

AMLX, IONS, CYTK, and SYRE Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

AMLX, IONS, CYTK, and SYRE Company Descriptions

Amylyx Pharmaceuticals NASDAQ:AMLX

Cytokinetics NASDAQ:CYTK

Ionis Pharmaceuticals NASDAQ:IONS

Spyre Therapeutics NASDAQ:SYRE

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools